A detailed history of Janus Henderson Group PLC transactions in Legend Biotech Corp stock. As of the latest transaction made, Janus Henderson Group PLC holds 2,359,056 shares of LEGN stock, worth $94.8 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
2,359,056
Previous 2,014,012 17.13%
Holding current value
$94.8 Million
Previous $113 Million 7.51%
% of portfolio
0.06%
Previous 0.06%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.5 - $57.22 $13.6 Million - $19.7 Million
345,044 Added 17.13%
2,359,056 $104 Million
Q1 2024

May 15, 2024

BUY
$55.06 - $69.99 $8.2 Million - $10.4 Million
148,855 Added 7.98%
2,014,012 $113 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $7.52 Million - $9.16 Million
131,379 Added 7.58%
1,865,157 $112 Million
Q3 2023

Nov 14, 2023

SELL
$63.16 - $76.5 $5.09 Million - $6.16 Million
-80,559 Reduced 4.44%
1,733,778 $116 Million
Q2 2023

Aug 14, 2023

SELL
$46.28 - $75.01 $5.77 Million - $9.36 Million
-124,754 Reduced 6.43%
1,814,337 $125 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $3.97 Million - $5.25 Million
91,449 Added 4.95%
1,939,091 $93.5 Million
Q4 2022

Feb 14, 2023

SELL
$38.8 - $55.46 $571,601 - $817,036
-14,732 Reduced 0.79%
1,847,642 $92.2 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $67.6 Million - $101 Million
1,771,275 Added 1944.34%
1,862,374 $76 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $3.06 Million - $5.01 Million
91,099 New
91,099 $5.02 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.